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Abstract
Background: Several studies have suggested an association between the functional Val158Met
polymorphism in the Catechol-O-Methyltransferase (COMT) gene and neurocognitive performance.
Two studies showed that subjects with the low activity Met allele performed better on the
Wisconsin Card Sorting Test (WCST) and another study found an effect on processing speed and
attention.
Methods: We set out to examine the association between the Val158Met polymorphism and
performance on neurocognitive tasks including those tapping working memory, attention and
speed, impulsiveness and response inhibition in a sample of 124 children with ADHD. Task
performance for each genotypic group was compared using analysis of variance.
Results: There was no evidence of association with performance on any of the neurocognitive
tasks.
Conclusions: We conclude that Val158Met COMT genotype is not associated with neurocognitive
performance in our sample.
Background
There has been recent interest in the role of the enzyme
Catechol-O-Methyltransferase (COMT) and prefrontal cog-
nition. COMT  together with monoamine oxidase cata-
lyzes degradation of catecholamines [1] with COMT being
responsible for the majority of dopamine catabolism in
the frontal cortex. The COMT gene is located on chromo-
some 22q11 [2]. Most molecular genetic interest in COMT
has focused on a Val158Met polymorphism which affects
the functional characteristics of the soluble isoform of
COMT, with the Met variant being associated with lower
activity and thermostability than the Val variant [3]. It is
unclear whether the polymorphism affects the function of
the membrane form of COMT, the major form in brain, in
a similar manner.
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A study by Egan et al (2001) [4] demonstrated that
patients with schizophrenia, unaffected siblings and con-
trols with the Met allele (low activity) performed better on
the Wisconsin Card Sorting Test (WCST), [5] a neurocog-
nitive test of prefrontal cognition [4]. This effect was more
prominent when an individual had two copies of the Met
allele. These findings have subsequently been replicated
in a normal volunteer sample [6] in which fewer persever-
ative errors on the WCST were made by subjects
homozygous for the Met allele. In another study of adult
volunteers tested using the Attention Network Test (ANT),
there was no association of the COMT variant with overall
reaction time or alerting but there was a trend towards
higher executive attention scores in those with the Met
allele [7]. A more recent study of patients with schizophre-
nia [8] also reported evidence of association of this COMT
variant with neurocognitive function, but with a measure
of processing speed and attention, rather than executive
function. Extending the sample used by Egan et al.,[4]
Goldberg et al. (2003)[9] set out to identify which specific
neurocognitive components within the WCST were
related to COMT Val158Met  differences within Schizo-
phrenic patients, their siblings and controls. Using the n-
back task, Goldberg et al. found that genotype differences
arose from measures of loading onto working memory
rather than general attentional deficits (measured by the
Continuous Performance task).
Attention Deficit Hyperactivity Disorder (ADHD) is a
highly heritable disorder [9] that affects between 2 and
6% of school children.[11] ADHD is characterised by
overactivity, impulsivity and inattention and is accompa-
nied by neurocognitive deficits, including those involving
executive function [12,13]. Neuropsychological [14] and
functional brain imaging studies [15,16] have implicated
the involvement of the prefrontal cortex and fronto-stri-
atal pathways in the aetiology of ADHD. Given the impor-
tance of the dopaminergic system in ADHD and the
associations between the neurocognitive abnormalities
and the Val158Met polymorphism, COMT is clearly a com-
pelling candidate gene for ADHD. However, most groups,
including our own, have failed to find evidence for associ-
ation between polymorphisms in this gene and ADHD
[17-21]. However, one study [22] has reported an associ-
ation between the high activity COMT allele (Val) and a
subtype of ADHD; DSM-IV hyperactive-impulsive type.
In this study, we have tested the hypothesis that the
Val158Met COMT polymorphism is associated with spe-
cific aspects of the ADHD phenotype, namely neurocogni-
tive function as assessed by tasks that measure attention,
response inhibition and, to some extent, working mem-
ory in children with ADHD.
Methods
Subjects
Families of children with suspected ADHD were recruited
from Child and Adolescent Psychiatry clinics from Greater
Manchester and Cheshire and invited to participate in a
genetic study. The study was approved by the North West
Multicentre Research Ethics Committee and informed
written consent and assent was obtained from the fami-
lies. Families of 124 children meeting ICD-10 criteria for
Hyperkinetic Disorder or DSM-III-R/IV criteria for ADHD,
who undertook the neurocognitive test battery and who
had been genotyped for the COMT variant were included
in the study. The sample were of British Caucasian origin
(including the grandparents of the index child), drug-
naïve, aged between 6 and 16 years (mean age 9.2 years,
standard deviation 1.8 years). 114 were male and 10 were
female. Exclusion criteria included children with an IQ
test score below 70, as assessed by the Wechsler Intelli-
gence Scale for Children-Third Edition UK (WISC-IIIUK),
[23] Tourette's syndrome, fragile X syndrome, epilepsy,
pervasive developmental disorder, or other major neuro-
logical disorders.
Assessment
A research diagnostic interview; the Child and Adolescent
Psychiatric Assessment (CAPA) [24] was completed with
the parents of the children by trained interviewers all of
whom had a degree in Psychology. To determine the diag-
nostic criterion of pervasiveness of symptoms across situ-
ations, the Child ADHD Teacher Telephone Interview
(CHATTI) [25] was used to also assess ADHD symptoms
and impairment at school. Interviews were audiotaped
and tapes were checked for consistency between inter-
viewers. Good inter-rater reliability was found [26]. Diag-
noses were then assigned according to ICD-10, DSM-IV
and DSM-III-R criteria. Further details of the assessment
and diagnostic process and sample characteristics have
been published previously [26].
Each child (n = 124) also completed the WISC-IIIUK to
assess IQ and to obtain a measure of working memory
derived from the Arithmetic and Digit Span subtests. The
forwards and backwards digit span subtest of the WISC III
was used as a measure of both attention and working
memory. At a second, school based, visit, a battery of neu-
rocognitive tasks were administered, including the Match-
ing Familiar Figures Test (MFFT), [27] the Continuous
Performance Test (CPT) [28] and the Stop and Go no Go
tasks from the MARS battery (Maudsley Attention and
Response Suppression task battery).[14] Data were
obtained for 114 children (10 children did not complete
the task battery due to administrative difficulties in setting
up a second visit at school). The MFFT measures impulse
control from reaction time (RT) for correct and incorrect
responses, and the number of pictures identified correctlyBMC Psychiatry 2004, 4 http://www.biomedcentral.com/1471-244X/4/15
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[27]. The CPT (identical pairs) measures inattention,
based on the number of targets missed (omission errors),
and sustained attention and impulse control, from the fre-
quency of incorrectly pressing a button (commission
errors) [28]. The display duration was 1 second with a
inter-stimulus delay of 1.5 seconds. The Stop task and Go
no Go task are measures of response inhibition. The
number of successful inhibitions and mean reaction times
(MRT) were obtained for these tests [14].
Genotyping
DNA was obtained from venous blood or mouthwash
samples using standard techniques. Polymerase chain
reactions (PCRs) were performed using the primers and
conditions described by Norton et al (2002) [29]. The
Val158Met polymorphism was genotyped by single nucle-
otide primer extension using a template-directed dye-ter-
minator incorporation assay with fluorescence
polarization detection [30] based upon AcycloPrime™ rea-
gents (Perkin Elmer Life Science Products, Boston, MA,
USA) according to the manufacturers recommendations.
Analyses were performed using a LJL Biosystems Analyst™
platform.
Statistics
Children were divided into 3 groups according to geno-
type (Val/Val, Val/Met and Met/Met) and task performance
was compared using one way analyses of variance
(ANOVA). A post hoc Bonferroni test was conducted for
multiple comparison. All reported p-values have been cor-
rected for multiple testing using Bonferroni statistics.
The groups were compared on all the task measures
together using ordinal regression analysis. Power calcula-
tions revealed that our sample provides over 80% power
to detect an effect size of 0.20 [31].
Results
Data from the WISC-III-R were available for 124 children
and the CPT, MFFT and MARS battery were completed on
114 children. The groups did not differ in terms of gender
or age. The mean scores on measures for each of the gen-
otypic groups are shown in table 1. The results show no
significant difference in attention, working memory or
performance on any of the neurocognitive tasks between
the three genotypic subgroups. These findings remained
when data were analysed for males only (data available
from authors). Similarly, where age was significantly asso-
ciated with neuropsychological measures, this factor was
used as a covariate in univariate ANOVAs. Again this did
not alter the results (data available from authors). No
neurocognitive measure accounted for a significant pro-
portion of the variance in logistic regression analysis.
Discussion
We set out to examine the association between the func-
tional Val158Met polymorphism in COMT and neurocog-
nitive task performance in a sample of children with
ADHD. There was no evidence of differences in perform-
ance according to the genotypic group. No differences
were found between those homozygous for the Met allele
and those with other genotypes (details available from
corresponding author on request). These findings contrast
with those of previous studies that have suggested an asso-
ciation between the COMT variant and prefrontal cogni-
tive functioning [4,6]. Two studies found an association
of COMT genotype and performance on the Wisconsin
Card Sorting task [4,6] in patients with schizophrenia and
in normal adult controls. However in another study of
patients with chronic schizophrenia [8], the COMT vari-
ant was associated with a measure of processing speed and
attention and in a different study of adult volunteers,
there was a trend toward association with executive atten-
Table 1: Comparison of neuropsychological test scores for each genotype and results of ANOVA
COMT Genotype
Met/Met Met/Val Val/Val ANOVA
Mean (SD) N Mean (SD) N Mean (SD) N F P
Working Memory Freedom from distractability Score 16.65 (4.60) 23 16.51 (4.58) 70 16.55 (5.76) 31 0.007 0.993
MFFT Mean Reaction Time of Incorrect 607.89 (441.08) 24 659.81 (628.27) 61 661.02 (508.34) 29 0.081 0.922
Mean Reaction Time of Corrrect 670.17 (498.93) 24 690.30 (669.07) 61 719.86 (578.75) 29 0.045 0.956
No. of Incorrect 40.29 (38.52) 24 50.57 (42.16) 61 40.28 (40.22) 29 0.896 0.411
CPT Comission errors 41.92 (43.65) 24 51.15 (42.52) 61 46.41 (40.81) 29 0.437 0.647
Omission errors 28.50 (41.74) 24 44.34 (47.57) 61 31.62 (42.54) 29 1.42 0.246
Stop Task % Inhibition 73.45 (25.78) 24 81.95 (23.92) 61 69.32 (32.51) 29 2.456 0.09
Mean Reaction time (ms) 383.13 (239.67) 24 325.13 (252.60) 61 341.05 (240.64) 29 0.475 0.623
Go No Go Task % Inhibition 72.86 (24.28) 24 79.61 (22.99) 61 68.52 (29.61) 29 2.075 0.13
Mean Reaction Time 316.40 (183.10) 24 258.66 (174.35) 61 276.66 (166.51) 29 0.946 0.391BMC Psychiatry 2004, 4 http://www.biomedcentral.com/1471-244X/4/15
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tion scores [7]. Given the postulated link between the
COMT variant and prefrontal cognition and the findings
of Bilder et al, 2002, [8] we had primarily been interested
in differences in the measures of response inhibition,
attention and working memory.
Our results suggest that in children with ADHD, not only
is there no evidence of association of the functional
COMT variant with ADHD [17-21] but that there is also
no association with neurocognitive task performance.
Our findings suggest that although ADHD is characterised
by neurocognitive deficits, in children with ADHD there
are no effects of COMT on neurocognitive functioning.
However there are alternative explanations for the results.
First, the sample size for which we have neurocognitive
data available is small and thus our negative findings
could be attributed to a lack of statistical power to detect
small effects; in the study by Egan et al, 2001, [4] the
COMT gentoype explained only 4% of the variance in the
frequency of perseverative errors and a larger sample than
ours would be needed to detect small effects. Second, pre-
vious studies have been based on patients with schizo-
phrenia (and their unaffected siblings) or normal adults.
It is plausible that the mechanisms that lead to impaired
cognitive functioning are different in ADHD and that
important developmental factors lead to contrasting find-
ings in children and adults. Moreover, our sample consists
of children who are drug naïve. This is a strength, but
again findings could vary depending on exposure to med-
ication. Finally, the Wisconsin Card Sorting Test was not
used in this study and some (but not all) of the previously
replicated findings were based on performance on this test
specifically. It has not yet been resolved how COMT may
be involved with neurocognitive functioning insofar as a
more recent study found no evidence of association with
the WCST but rather with processing speed and attention
[8]. Nevertheless, it could be argued that our measures did
not specifically assess prefrontal cognition in the same
way that the Wisconsin Card Sorting Test does. In future
studies, it would be advantageous to use the WCST.
Conclusion
We find no evidence of an association between the COMT
Val158Met genotype and performance on a variety of neu-
rocognitive tasks in children with ADHD. Family-based
studies of the COMT gene in this sample may shed further
light on any association and are currently underway. Our
findings indicate that if the COMT gene is involved in
ADHD, or a specific phenotypic manifestation of the dis-
order, as has been suggested, such associations do not lie
in differential performance on the neurocognitive tasks
undertaken in this study.
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